Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria

被引:5
作者
Bejon, Philip [1 ]
Mwangi, Tabitha
Lowe, Brett
Peshu, Norbert
Hill, Adrian V. S.
Marsh, Kevin
机构
[1] Kenya Govt Med Res Ctr, Ctr Geog Med Res, Nairobi, Kenya
[2] Univ Oxford, Ctr Clin Vaccinol & Tropic Med, Oxford OX3 7LJ, England
[3] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England
[4] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
基金
英国惠康基金;
关键词
Plasmodium falciparum; malaria attributable fraction; specificity; febrile malaria; definition;
D O I
10.1016/j.vaccine.2007.07.057
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In clinical trials, the specificity of the disease endpoint is critical to an accurate estimate of vaccine efficacy. We used a logistic regression model to analyse parasite densities among children before and after treatment with antimalarials, in order to estimate the impact that clearing asymptomatic parasitaemia had on the specificity of the endpoint of febrile malaria. The malaria attributable fever fraction was higher after antimalarial treatment (i.e. fever and parasitaemia were more likely to be causally related), implying that drug treatment prior to monitoring decreased the misclassification of febrile malaria. In intervention studies with febrile malaria as an endpoint, clearing asymptomatic parasitaemia increases the study's power more effectively than raising the threshold parasitaemia. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:8198 / 8202
页数:5
相关论文
共 17 条
[1]   Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Aide, P ;
Sigauque, B ;
Milman, J ;
Mandomando, I ;
Bassat, Q ;
Guinovart, C ;
Espasa, M ;
Corachan, S ;
Lievens, M ;
Navia, MM ;
Dubois, MC ;
Menendez, C ;
Dubovsky, F ;
Cohen, J ;
Thompson, R ;
Ballou, WR .
LANCET, 2005, 366 (9502) :2012-2018
[2]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[3]   RANDOMIZED TRIAL OF EFFICACY OF SPF66 VACCINE AGAINST PLASMODIUM-FALCIPARUM MALARIA IN CHILDREN IN SOUTHERN TANZANIA [J].
ALONSO, PL ;
SMITH, T ;
SCHELLENBERG, JRMA ;
MASANJA, H ;
MWANKUSYE, S ;
URASSA, H ;
DEAZEVEDO, IB ;
CHONGELA, J ;
KOBERO, S ;
MENENDEZ, C ;
HURT, N ;
THOMAS, MC ;
LYIMO, E ;
WEISS, NA ;
HAYES, R ;
KITUA, AY ;
LOPEZ, MC ;
KILAMA, WL ;
TEUSCHER, T ;
TANNER, M .
LANCET, 1994, 344 (8931) :1175-1181
[4]  
Armstrong Schellenberg J. R. M., 1994, Parasitology Today, V10, P439
[5]   A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya [J].
Bejon, Philip ;
Mwacharo, Jedidah ;
Kai, Oscar ;
Mwangi, Tabitha ;
Milligan, Paul ;
Todryk, Stephen ;
Keating, Sheila ;
Lang, Trudie ;
Lowe, Brett ;
Gikonyo, Caroline ;
Molyneux, Catherine ;
Fegan, Greg ;
Gilbert, Sarah C. ;
Peshu, Norbert ;
Marsh, Kevin ;
Hill, Adrian V. S. .
PLOS CLINICAL TRIALS, 2006, 1 (06)
[6]   ACELLULAR PERTUSSIS VACCINES - EFFICACY AND EVALUATION OF CLINICAL CASE DEFINITIONS [J].
BLACKWELDER, WC ;
STORSAETER, J ;
OLIN, P ;
HALLANDER, HO .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1991, 145 (11) :1285-1289
[7]   Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial [J].
Bojang, KA ;
Milligan, PJM ;
Pinder, M ;
Vigneron, L ;
Alloueche, A ;
Kester, KE ;
Ballou, WR ;
Conway, DJ ;
Reece, WHH ;
Gothard, P ;
Yamuah, L ;
Delchambre, M ;
Voss, G ;
Greenwood, BM ;
Hill, A ;
McAdam, KPWJ ;
Tornieporth, N ;
Cohen, JD ;
Doherty, T .
LANCET, 2001, 358 (9297) :1927-1934
[8]   A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea [J].
Genton, B ;
Betuela, I ;
Felger, I ;
Al-Yaman, F ;
Anders, RF ;
Saul, A ;
Rare, L ;
Baisor, M ;
Lorry, K ;
Brown, GV ;
Pye, D ;
Irving, DO ;
Smith, TA ;
Beck, HP ;
Alpers, MP .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (06) :820-827
[9]   Vaccines for preventing malaria (blood-stage) [J].
Graves, P. ;
Gelband, H. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04)
[10]   Sensitivity, specificity, and vaccine efficacy [J].
Lachenbruch, PA .
CONTROLLED CLINICAL TRIALS, 1998, 19 (06) :569-574